Profiling the production of antimicrobial secondary metabolites by xenorhabdus khoisanae J194 under different culturing conditions by Booysen, Elzaan et al.
Profiling the Production of
Antimicrobial Secondary Metabolites
by Xenorhabdus khoisanae J194
Under Different Culturing Conditions
Elzaan Booysen1, Marina Rautenbach2*, Marietjie A. Stander2,3 and Leon M. T. Dicks1*
1Department of Microbiology, Stellenbosch University, Stellenbosch, South Africa, 2Department of Biochemistry, Stellenbosch
University, Stellenbosch, South Africa, 3LCMS Central Analytical Facility, Stellenbosch University, Stellenbosch, South Africa
Species from the genus Xenorhabdus, endosymbiotic bacteria of Steinernema
nematodes, produce several antibacterial and antifungal compounds, some of
which are anti-parasitic. In this study, we report on the effect growth conditions
have on the production of antimicrobial compounds produced by Xenorhabdus
khoisanae J194. The strain was cultured in aerated and non-aerated broth,
respectively, and on solid media. Production of antimicrobial compounds was
detected after 24 h of growth in liquid media, with highest levels recorded after
96 h. Highest antimicrobial activity was obtained from cells cultured on solid media.
By using ultraperformance liquid chromatography linked to mass spectrometry and
HPLC, a plethora of known Xenorhabdus compounds were identified. These
compounds are the PAX lipopeptides (PAX 1′, PAX 3′, PAX 5, and PAX 7E),
xenocoumacins and xenoamicins. Differences observed in the MS-MS fractionation
patterns collected in this study, when compared to previous studies indicated that this
strain produces novel xenoamicins. Three novel antimicrobial compounds, khoicin,
xenopep and rhabdin, were identified and structurally characterized based on MS-MS
fractionation patterns, amino acid analysis and whole genome analysis. The various
compounds produced under the three different conditions indicates that the secondary
metabolism of X. khoisanae J194 may be regulated by oxygen, water activity or both.
Based on these findings X. khoisanae J194 produce a variety of antimicrobial
compounds that may have application in disease control.
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INTRODUCTION
Careless and frequent use of antibiotics have led to an increase in resistance (D’Costa et al., 2011; Fair and
Tor, 2014; Ventola, 2015). With only a handful novel classes of antibiotics approved during the last three
decades (Spellberg et al., 2008), many researchers are of the opinion that we have entered a post-antibiotic
era (Lee Ventola, 2015). Novel antimicrobial compounds with modes of activity different to traditional
antibiotics may be the answer. This is, however, a challenge, as many newly discovered antimicrobial
compounds do not pass stringent safety tests, or production costs are too high.
Approval of daptomycin, an antimicrobial lipopeptide from Streptomyces roseosporus, by the
Food and Drug Administration (FDA) in 2003 (Arbeit et al., 2004) and the re-approval of polymyxin
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B, produced by Bacillus polymyxa (Zavascki et al., 2007), led to
renewed interest in antimicrobial peptides. Most bacteria produce
antimicrobial compounds, either for survival, or as a defense
mechanism. Many of these compounds target cellular structures
such as cell walls and membranes, pathways involved in energy
(ATP)-production, or protein- and, nucleic acid synthesis
(Kaufman, 2011).
Bacteria living in symbiosis with soil dwelling nematodes
produce several antimicrobial compounds. Xenorhabdus, a
member of the family Enterobacteriaceae, is closely associated
with Steinernema entomopathogenic nematodes that infect the
larvae of Galleria mellonella Linnaeus (Dunphy and Webster,
1991). A single, or at the most only a few strains, of a
Xenorhabdus sp. develops a symbiotic relationship with the
nematode and keeps the host free from other bacteria. This
suggests that the invading strain(s) produce either a single
broad spectrum antimicrobial compound, or several
compounds. As soon as the nematode invades the insect,
Xenorhabdus elicits the production of a plethora of secondary
metabolites, including antimicrobial peptides, polyketides,
proteases and hydrolytic exo-enzymes (Dreyer et al., 2018). In
the case of Xenorhabdus budapestensis, production of the
immune suppressor prophenoloxidase leads to an increase in
quinones, killing the insect host (Yang et al., 2012).
A total of 23 antimicrobial compounds produced by
Xenorhabdus spp. have been described, of which the majority
have bactericidal and fungicidal activity (reviewed by Dreyer
et al., 2019). These include xenocoumacins (Park et al., 2009;
Reimer et al., 2009), bicornitun (Böszörményi et al., 2009), PAX
peptides (Gualtieri et al., 2009; Dreyer et al., 2019), xenorhabdins
(McInerney et al., 1991a; McInerney et al., 1991b), xenorxides
(Webster et al., 1996) and benzylideneacetone (Ji et al., 2004). A
few antimicrobial compounds are also insecticidal and anti-
parasitic (Ji et al., 2004; Crawford et al., 2011; Crawford et al.,
2012; Grundmann et al., 2013; Zhou et al., 2013; Fuchs et al., 2014;
Kronenwerth et al., 2014; Proschak et al., 2014; Reimer et al.,
2014; Zhao et al., 2018; Hacker et al., 2018). Also refer to review
by Booysen and Dicks (2020) that focusses on the potential of
Xenorhabdus for antibiotic production.
Xenocoumacins are one of the major antimicrobial
compounds produced by Xenorhabdus spp. and was first
described by McInerney et al. (1991a, b). These compounds
are known as benzopyran-1-one derivates encoded by the
xcnA-N gene cassette on the genome of Xenorhabdus
nematophilia (Park et al., 2009). A total of six xenocoumacins
were identified, although xenocoumacins I and II are the two
mainly expressed by the xcnA-N gene cassette (Reimer et al.,
2009). Both xenocoumacins I and II show antimicrobial activity,
although xenocoumacin I is more active and kills bacteria and
fungi (McInerney et al., 1991b).
Bicornitun is an arginine-rich non-ribosomal antifungal
peptide produced by X. budapestensis, first described by
Böszörményi et al. (2009). Four different bicornitun
compounds have been described, i.e., bicornitun A1, A2, B
and C. Lysine-rich cyclic lipopeptides, the PAX peptides, were
first reported by Gualtieri et al. (2009). An additional eight PAX
peptides were later described by Fuchs et al. (2011). Genes
encoding the PAX peptides are located in the paxABC gene
cassette (Fuchs et al., 2011). PAX 5 is active against
Pseudomonas aeruginosa and Escherichia coli, while PAX 3,
PAX 4 and PAX 5 are active against Streptococcus epidermidis.
All PAX peptides are active against Fusarium
oxysprum.(Gualtieri et al., 2009) No cytotoxic activity was
recorded against Chinese Hamster Ovary cells (Gualtieri et al.,
2009).
Xenorhabdins and xenorxides are dithiolopyrrolones
derivatives, first described by McInerney et al. (1991a, b) and
Webster et al. (1996), respectively. These compounds are known
for their wide-spread antibacterial, antifungal and insecticidal
activity (McInerney et al., 1991a; McInerney et al., 1991b; Li
et al., 2014). Benzylideneacetone, produced by X. nematophilia,
is used as a flavoring additive in cigarettes, food products,
detergents and cosmetics (Dreyer et al., 2018). Although this
compound have been used in industry for decades, the
antibacterial activity of benzylideneacetone was only
discovered in 2004 (Ji et al., 2004).
Most of the Xenorhabdus antimicrobial compounds are
produced by non-ribosomal peptide synthesis (NRPS)
(Fuchs et al., 2011; Zhou et al., 2013; Kronenwerth et al.,
2014; Hacker et al., 2018), or a combination of polyketide
synthesis (PKS) and NRPS (NRPS/PKS) (Qin et al., 2013;
Fuchs et al., 2014; Guo et al., 2017). Although not that
common, some antimicrobial peptides are also produced by
ribosomal peptide synthesis (RPS) (Singh and Banerjee, 2008).
Examples of antimicrobial compounds produced by NRPS are
xenoamicins (Zhou et al., 2013), PAX peptides (Fuchs et al.,
2011) and nematophin (Cai et al., 2017), while xenocoumacins
and fabclavins are produced by NRPS/PK synthesis (Guo et al.,
2017). Xenocin (Singh and Banerjee, 2008) and xenorhabdicin
(Thaler et al., 1995) are the only two RPS peptides described to
date. For a more extensive review on antimicrobial compound
synthesis by Xenorhabdus spp., the reader is referred to
Booysen and Dicks (2020). Xenorhabdus peptides are
usually synthesized by the non-ribosomal synthetases,
hybrid non-ribosomal/polyketide synthetases or ribosomes
and can include fatty acid or polyketide chains (Gualtieri
et al., 2009; Reimer et al., 2011; Zhou et al., 2013), while
non-peptide compounds like benyzlideacetone does not
contain any amino groups (Dreyer et al., 2018).
Only a few reports have been published on growth conditions
affecting the production of antimicrobial compounds, and only
those produced by X. nematophilia and Xenorhabdus bovienii.
These included the effect of pH (Wang et al., 2011b), incubation
temperature (Chen et al., 1996; Wang et al., 2008a), agitation,
aeration (Wang et al., 2008a) and nutrients(Chen et al., 1996;
Wang et al., 2008b; Crawford et al., 2010; Wang et al., 2011a). In
this study, we report on secondary metabolites and antimicrobial
compounds produced by X. khoisanae J194, a bacterium
indigenous to South Africa identified by Ferreira et al. (2013),
and the production of these compounds when cells were cultured
in aerated broth, non-aerated broth, and on the surface of
solid media.
Frontiers in Chemistry | www.frontiersin.org March 2021 | Volume 9 | Article 6266532
Booysen et al. Secondary metabolites of X. khoisanae J194
RESULTS
Influence of Culturing and Extract
Procedure on Antimicrobial Activity
Various studies have shown that culturing conditions have an
effect on bacterial metabolism and production of secondary
metabolites. This study showed that the pH of non-aerated
cultures (method A) increased from 6.0 to 8.5 over 96 h, while
the pH of cells grown under aerated conditions (method B)
decreased from 6.0 to 5.5 over the same period (Figure 1).
Compared to the aerated cultures (method B) a rapid increase
in OD (biomass) was observed for the non-aerated cultures
(method A) of strain J194 (Figure 1). Cells of J194 cultured
under oxygen-limiting conditions always produced a yellow
pigment, that was not observed to the same extent when J194
was cultured under oxygen rich conditions.
During 96 h of growth under non-aerated conditions,
4,196 mg freeze-dried material was collected from CFSs. Of
this, 2,863 mg was from the oily bottom fraction (NAO, oily
fraction from a non-aerated broth culture) and the rest from
the acetonitrile upper fraction (NAA, acetonitrile fraction of
a non-aerated broth culture). Over the same period, 1,010 mg
freeze-dried material was isolated from the CFSs of aerated
cultures (AB, fraction from an aerated culture). Cells grown
on the surface of TSA plates produced 5,504 mg of
hydrophobic/amphipathic material (SM, extract from a
culture grown on the surface of solid media). Less than
100 mg of intracellular material was extracted from aerated
and non-aerated cultures.
The antimicrobial activity of material collected from the CFSs
of non-aerated and aerated cultures, and from surface-grown cells
after treatment with XAD beads, varied considerably. After 24 h
of incubation, antimicrobial activity was recorded in CFSs
collected from non-aerated cultures and cultures grown on the
surface of TSA (Figure 2). However, after 48 h of incubation in
liquid media, all samples, except for the biomass extract, inhibited
the growth of Staphylococcus aureus ATCC 25923, Listeria
monocytogenes EDGe, Escherichia coli Xen 14 and
Pseudomonas aeruginosa ATCC 27853. Highest levels of
activity were recorded after 96 h of incubation in non-aerated
broth and on the agar surface (Figure 2). NAA material collected
using method A showed highest activity against E. coli Xen 14,
while AB material collected using method B and hydrophobic
material collected using method C showed the highest activity
against P. aeruginosa ATCC 27853 (Table 1). Overall,
hydrophobic compounds isolated with method C (SM
fractions) displayed the highest specific activity against P.
aeruginosa ATCC 27853 (350 mm2/mg), E. coli Xen 14
(263 mm2/mg), S. aureus Xen 31 (275 mm2/mg) and L.
monocytogenes EDGe (263 mm2/mg) (Table 1). NAA material
collected from of non-aerated cultures were not active against S.
aureus ATCC 25923, S. aureus Xen 31 and Streptococcus
epidermidis SE1 (Table 1).
UPLC-MS Fingerprinting of Culture Extracts
By performing UPLC-MS, we characterized the compounds from
the antibiotic/antimicrobial complex based on elution from the
C18 matrix, signal intensity and accurate Mr. The compounds
were grouped into early eluting compounds (0–6 min),
representing polar/hydrophilic and amphipathic compounds
(Figure 3) and the mid-to-late gradient eluting compounds
(6–17 min), representing amphipathic and hydrophobic
compounds (Figure 4).
A complex mixture of 44 novel metabolites were selected on
the grounds of ion intensity and confirmation of an elution peak
in the UPLC-MS analysis (Figures 3, 4; Supplementary Figures
S1–5 and Table 2). From these analyses we generated a heatmap
(Table 2) to fingerprint and compare the culture conditions and
extract fraction. From the fingerprinting we observed that the
more polar and amphipathic compounds (Rt 0–6 min) were
found in the broth culture extracts (NAA, NAO and AB)
(Figure 3; Table 2). The more amphipathic and hydrophobic
compounds eluting from 7–16 min were observed primarily in
the solid media extract (SM) with some in the oily fraction of the
non-aerated broth culture extract (NAO) (Figure 4; Table 2)
Over the first 6 min a diverse number of compounds were
identified in the UPLC analysis of which 19 were selected for
fingerprinting (Figure 3; Supplementary Figure S1 and Table 2).
Similar polar compounds were found in NAO and SM extracts,
while the profiles of NAA and AB correlated (Figure 3;
Supplementary Figures S1, S2), with latter possibly due to
the aqueous nature of the extract and culture media. The
heatmap in Table 2 indicated the differences between the
extracts. Notably the compounds observed with high ion
intensity, 8 (m/z  427.3), 16 (m/z  889.5), 17 (m/z  671.4),
18 (m/z  407.2) were primarily found in the NAO and SM
FIGURE 1 | Changes in growth (optical density) and culture pH of X.
khoisanae J194 under non-aerated (method A) and aerated (method B)
culturing in broth over 4 days. Data depicts the mean of the three independent
cultures. Error bars show standard deviation.
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extracts. Only compounds 15 (m/z  1124.6) is observed
primarily in the more aqueous extracts, AB and NAA. We
were able to purify compounds 8, 17, 15 and 18 for further
study (refer to discussion below).
In the mid-gradient to late gradient (6–17 min) a plethora of
small compounds are observed for the SM and less so for the
NOA fraction (Figure 4; Supplementary Figures S3, S4 and
Table 2). None of the compounds show a particularly high
intensity in comparison with those eluting from 1–6 min of
after 13 min.
The hydrophobic compounds (34–44) eluting after 13 min
were all about 1.3 kDa with 14, 16 and 22 Da differences (Table 2),
which indicated the possibly of a related peptide complex. We
identified thee compounds, 39 (m/z  1328.9) and 42 (m/z 
1314.8) with 44 (m/z  1336.8) the Na-adduct of 42 for
purification and further analysis. Refer to discussion below.
FIGURE 2 |Growth inhibition (%) of different target bacteria, S. aureus (A), L. monocytogenes (B), E. coli (C) and P. aeruginosa (D), as observed by changes in OD
at 600 ± 5 nm, compared to control cultures, after exposure to the five different X. khoisanae J194 culture extracts. The response (OD at 600 nm) of the selected target
bacteria S. aureus ATCC 25923, L. monocytogenes EDGe, E. coli Xen 14 and P. aeruginosa ATCC 27853, are shown after 24 h exposure to extracts and incubation at
37°C. Three cultures of each target organismwere treated with cell-free supernatants (CFS) of X. khoisanae J194 cultured in non-aerated broth (Method A), aerated
broth (Method B) and on the surface of solid media (Method C), respectively. CFSs of non-aerated culture were separated into the acetonitrile (NAA) and organic fractions
(NAO) (Method A). The hours indicated in the graphs refer to the time at which CFSs were collected and freeze-dried.
TABLE 1 | Antibacterial activity of extracts collected from Xenorhabdus cultures grown under different conditions.








P. aeruginosa ATCC 27853 100 175 300 350
E. coli Xen 14 175 150 150 263
S. aureus ATCC 25923 0 100 163 113
S. aureus Xen 31 0 138 250 275
S. epidermidis SE1 0 163 175 150
L. monocytogenes EDGe 63 113 213 263
Activity is indicated by clear zone area (mm2/mg) in the agar well diffusion assay.
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Identification of Known Compounds
AntiSMASH identified 17 known biosynthetic gene clusters, of
which eight were native to Xenorhabdus spp. (Figure 5). This
presence of the xenocoumacin, xenoamicin and PAX peptide
biosynthetic gene clusters led us to search for these compounds in
the extracts.
Closer inspection of the compounds eluting from 1 to
6 min revealed compound 8 (m/z  1,078.8) as PAX 7E in the
NAA extract. We also found PAX1′, PAX3′ and PAX5 at
lower levels in this extract (Figure 6B). The production of
the PAX peptides in this Xenorhabdus strain was much
lower than that found by Dreyer et al. (2019), and we
were unable to purify any member of this family further.
However, accurate mass analysis and the PAX biosynthetic
gene cluster in this strain’s genome supported our
identification (Table 3).
Compound 18 (m/z  407.2) that eluted early at 3.71 min was
observed in the NAO and SM fractions (Table 2). The compound
displays a distinct yellow color and was purified and subsequently
identified as xenocoumacin II (Figure 5; Supplementary Figure
S6 and Table 3).
With the analysis of the late eluting compounds, we noted a
compound range around 1.3 kDa that may be part of a peptide
complex. As the xenoamicin biosynthetic gene cluster were found
in this strain’s genome (Figure 5) this family was considered as
possible candidate compounds. These peptide complexes were
primarily identified in the SM fraction, although some of the
members were also observed in the NAO fraction. We were able
to co-purify compound 42 (m/z  1314.8) and compound 38 (m/z
 1328.8) (Supplementary Figure S7; Table 2) and confirmed
that both are members of the xenoamicin family (Figure 6;
Supplementary Figure S7 and Table 3). However, the MS-MS
structural analysis of compounds 38 and 42 showed a number of
different fragments to that of xenoamicin G and B/C, respectively.
Compound 38 shares the b1–b5 fragments with Xenoamicin B
and X (Zhou et al., 2013) but differs by +14 Da in the observed y
fragments. This indicated either a −CH2CH3 group in
R4(Val→Ile) or iso/secondary butyl group in R5 (Val→Ile/Leu)
FIGURE 3 | UPLC-MS of the early eluting components (0–6 min) from the four X. khoisanae J194 extracts that showed antibacterial activity: (A) aqueous fraction of
non-aerated broth culture, (B) NAO fraction of non-aerated broth culture, (C) fraction from aerated broth culture and (D) extract from culture grown on surface of solid
medium. The masses in the spectra are protonated masses of the most prominent detected compounds.
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(Figure 6; Supplementary Figure S7). Compound 38 was labeled
as xenoamicin B2v→I/L. Compound 42 shares the b1–b4
fragments with Xenoamicin B and C (Zhou et al., 2013) but
differs by −14 Da in b5 indicating a −CH3 group in R3(Ile→Val).
Compound 42 also differed in the y’8 fragment by +14 Da. This
indicated either a −CH2CH3 group in R4 (Val→Ile) or iso/
secondary butyl group in R5 (Val→Ile/Leu) (Figure 6;
Supplementary Figure S7). Compound 42 was labeled as
xenoamicin B3I→V, I/L→V. Compound 37 (m/z  1330.8), was
also further characterized. This compound was labeled as a
xenoamicin B1+OH, x after its fragmentation pattern was
compared with that of compound 42 (Supplementary Figure
S8; Table 3). The MS-MS analysis indicated that the terminal
group was hydroxylated while R3 group or residue was different
from that of 42 and other reported xenoamicins. A number of
other xenoamicins were also found in this peptide complex.
Compound 34 with an identical Mr to xenoamicin D was
denoted xenoamicin D1. Compound 35 and its sodium adduct
(36) had three elution peaks (Table 2) indicating three different
compounds with all three having an identical mass to xenoamicin
A (Zhou et al., 2013) and was denoted xenoamicin A1,2,3
(Table 3). Three more compounds may be part of this
complex, 40 (m/z  1312.8), 41 (m/z  1331.7) and 43 (m/z 
1352.8). This xenoamicin complex contains novel analogues that
warrants future exploration.
Novel Antimicrobial Compounds
The observed antibacterial activity of SM, NAA and NAO could
be due to the PAX peptides and/or xenocoumacin II. However,
other novel compounds could also contribute to this observed
antibacterial activity. Furthermore, no known compounds with
antibacterial activity were identified in the AB fraction, which
could indicate that this fraction contains novel antimicrobial
components. Twenty-one possible NRP synthetase operons
were identified after utilizing the tblastn function of the
NCBI website. This was further narrowed down to two
putative operons by searching for the core motifs of the
catalytic domains of the NRP synthetases. From this result
we then predicted that at least two small non-ribosomally
synthesized antimicrobial peptides or peptide analogues may
be present in the extracts. Refer to Supplementary Figure S9 for
the protein sequences of the two putative domains.
Three possible novel compounds and putative non-ribosomal
antibacterial peptides namely compounds 8 (m/z  427.3), 17
(m/z  671.4) and 15 (m/z  1124.6), were identified and purified
from the various extracts (Figures 7–9). All three compounds
were produced at appreciable amounts that assisted further
purification to >75% purity (Figures 7–9). The antimicrobial
activity of the three compounds were confirmed by screening
the purified compounds against a library of bacterial targets
(Table 4).
Compound 8–Khoicin
The first novel compound was named khoicin (8,m/z  427.3) and
exhibited a broad spectrum of potent Gram-positive and Gram-
negative activity (Table 4). It is mainly produced in oxygen-
limiting conditions and the highest amounts were extracted
from a non-aerated broth culture (NAO) and a culture grown
FIGURE 4 | UPLC-MS of the mid-gradient eluting components (6–17 min) from the four X. khoisanae J194 extracts that showed antibacterial activity: (A) NAO
fraction of nonaerated culture in broth, (B) extract from culture grown on surface of solid media. The masses in the spectra are protonated masses of the most prominent
detected compounds.
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on solid media (SM). It was detected in the extracts in the
following order: NAO>SM>AB>NAA (Figures 3B,D; Table 4).
We determined the accurate mass of khoicin and derived its most
probable elemental composition as C20H39N6O4. The MS-MS
structural analysis of khoicin revealed that it fragmented into
two major fragments, namely a dehydration product as m/z 
409.3 and a fragment ion at m/z  367.3 which could be the result
of the loss of an acetyl (CH2CO) group from the molecular ion
(Figure 7). The rest of the fragment ions were at a much lower
intensity. However, we could identify a fragment of 113.08 that
indicated a Leu/Ile residue correlating with an immonium ion of
Ile/Leu at m/z  86.098. The fragments ions 254.197 and 227.101
could be mapped to an acetylated dipeptide containing Leu/Ile,
respectively. One of the minor fragments atm/z  156.113 mapped
to Arg, which could explain the early elution of this compound.
These results further indicate the peptide nature of khoicin and
considering the elemental composition khoicin could consist of a
formylated Arg linked to an acetylated Leu/Ile dipeptide, with Mr
426.2949, correlating with the experimental Mr of 426.2956
(−2 ppm mass error) (Figure 7).
Compound 15–Xenopep
Compound 15, named, xenopep (m/z  1124.6), was one of the
early eluting peptide-like compounds primarily produced by
aerated broth cultures (AB), suggesting that xenopep
production could be oxygen dependent (Table 2). We were
able to purify xenopep from AB cultures to >85% purity for
further analysis (Figures 8A,B). Xenopep (16) is only active
against Gram-positive bacteria (S. aureus, S. epidermidis and L.
monocytogenes) and could thus be responsible for the
inhibition of S. epidermidis and L. monocytogenes in AB and
NAA extracts (Table 1 and Table 4). The purified peptide was
subjected to amino acid analysis which revealed the amino acid
TABLE 2 |Heatmap of UPLC-MS fingerprinting of secondary metabolite profiles in
the extracts of the three different Xenorhabdus cultures (refer to Figures 3, 4).
Compound
Number




NAA NAO AB SM
1 2.74 1 1 98 0 479.298
2 2.75 49 16 32 4 652.401
3 2.77 4 30 8 59 445.313
4 2.81 37 24 38 2 751.367
5 2.84 45 21 32 2 758.407
6 2.85 29 34 30 7 558.330
7 2.89 17 44 27 11 627.349
8 2.92 8 53 12 26 427.302
9 2.98 1 0 99 0 474.342
10 2.98 17 25 36 23 473.275
11 3.01 33 24 32 12 1100.576
12 3.02 30 9 59 3 530.297
13 3.02 54 27 18 1 1025.567
14 3.16 91 7 2 0 1078.806*
15 3.40 48 4 43 4 1124.634
16 3.50 9 29 49 13 889.481
17 3.59 5 60 7 28 671.413
18 3.75 2 68 0 29 407.217*
19 4.42 4 39 7 50 434.265
20 7.05 3 2 10 86 881.543
21 8.02, 9.59 3 46 1 50 354.220
22 8.93 4 12 5 80 758.455
23 9.90 3 28 4 66 394.211
24 9.90 1 14 2 83 372.229
25 10.47 5 28 4 62 355.198
26 10.49 1 18 1 80 333.217
27 11.14 1 7 2 90 386.244
28 11.35 2 5 4 89 792.416
29 11.82 1 17 4 77 719.432
30 11.83 2 1 11 87 1437.882
31 11.85 5 28 12 56 741.431
32 11.90 3 13 2 83 347.235
33 12.20 2 7 2 89 753.433
34 13.33 0 7 9 84 1286.809
35 13.7,
14.2, 14.7
0 24 0 76 1322.803
36 13.8,
14.2, 14.8
0 15 1 84 1300.823
37 14.63 0 0 4 96 1330.840
38 14.74 0 78 0 22 1350.832
39 14.86 0 66 2 32 1328.853
40 14.89 0 7 1 92 1312.822
41 15.97 0 16 1 83 1331.860
42 15.97 0 17 1 82 1314.838
43 15.97 0 23 7 70 1352.794
44 15.99 0 32 1 67 1336.817
The ions were selected from the top 50 most abundant ions after confirmation in the
UPLC-MS profile. Refer to Supplementary data on analyses.
The numbers within blocks indicate the relative signal in the ESMS detection of the
different compounds (total sample signal was normalized and then the relative signal for
each ion was calculated). The m/z values in bold indicated most abundant ions, those
underlined were purified further for more detailed structural analyses (refer to Figures
5–8; Supplementary Figures S1–4) and known compounds and detected metabolites
(refer to Figure 5; Table 3) are indicated with an * and #, respectively.
FIGURE 5 | Graph depicting the various operons identified in the whole
genome of X. khoisanae J194 by the antiSMASH algorithms. The gray bars
indicate operons native to Xenorhabdus bacteria. Operons for xeneprotides,
bicornutin, ambactin, taxlllaid and luminmide were also detected by
antiSMASH, but was not identified in the crude extracts. The gray hashed bars
indicate detected secondary metabolite products related to the expression of
these genes (refer to Table 3). The clear bars indicate other putative operons
identified in the whole genome.
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composition to contain Val, Leu, Lys, Glu, Phe and three Pro
residues.
We considered the two NRP synthetase operons to assist
with the structure determination of xenopep, the first putative
operon is located within node 7 and consist out of five genes
encoding for the nine amino acids, with a predicted sequence
of Gln-Haa-Pro-Pro-Ile-Gln-Pro-Val (Haa  hydrophobic
amino acid) (Figure 8E). The sequence partially correlated
with the determined amino acid composition. A conservative
replacement of Ile with Leu improved this correlation, but one of
the Gln residues must be replaced with Lys for a better
correlation. The high-resolution MS-MS sequencing did not
reveal a classical b- and y’’-ion pattern of a linear peptide acid
but yielded a number of internal fragments (Figure 8C).
Using the MS-MS analysis and predicted sequence from the
xenopep putative operon, a working sequence was deduced as
Lys-Haa-Pro-Pro-Leu-Gln-Pro-Val (Figure 8D), with Haa an
undetermined hydrophobic residue.
FIGURE 6 |High resolution MS analysis and the structures of compounds in the three most prominent known families identified in J194 culture: (A) Xenocoumacin
II, identified with a * (McInerney et al., 1991b; Reimer et al., 2009); (B) PAX peptides (Fuchs et al., 2011; Dreyer et al., 2019), and (C) xenoamicins (Zhou et al., 2013 and
this study). Refer to Supplementary Figure S6, S7 for more structural analyses details.
TABLE 3 | Summary of previously identified secondary metabolites in the extracts of the three different Xenorhabdus cultures using high resolution UPLC-MS and MS
analysis, as well as genetic analysis to confirm group identity. Refer to Figures 2–4; Table 2 for UPLC-MS and Supplementary Figures S1, S2 and S5 for high
resolution MS analyses and structures.
Nr
Experimental Mr Proposed Identity Theoretical Mr Mass error
(ppm)
Comment/Reference
Protonated Sodiated Protonated Sodiated
- 1050.7719 - PAX5 1050.7766 - 4 Low concentration, Fuchs et al. (2011)
- 1052.7937 - PAX1′ 1052.7923 - −1 Low concentration, Fuchs et al. (2011)
- 1066.8075 - PAX3′ 1066.8079 - 0.4 Low concentration, Fuchs et al. (2011)
8 1078.8058 - PAX7E 1078.8079 - 2 Low concentration, Dreyer et al. (2019)
18 407.2171 - Xenocoumacin II 407.2182 - 3 Reimer et al. (2011), Dreyer et al. (2019)
34 1286.8077 1308.7849 Xenoamicin D1 1286.8077 1308.7901 0, 4 Novel Xenoamicin? Zhou et al. (2013), this study
35, 36 1300.8235 1322.8052 Xenoamicin A1,2,3 1300.8238 1322.8058 0.2, 0.5 Novel Xenoamicins? Zhou et al. (2013), this study
37 1330.8326 - Xenoamicin B2 +OH, x 1330.8344 - 1 Novel Xenoamicin, Zhou et al. (2013), this study
38, 39 1328.8552 1350.8311 Xenoamicin B1 (V→I/L) 1328.8552 1350.8371 0, 4 Novel Xenoamicin, Zhou et al. (2013), this study
42, 44 1314.8390 1336.8177 Xenoamicin B2 (I→V, I/L→V) 1314.8395 1336.8215 0.4, 3 Novel Xenoamicin, Zhou et al. (2013), this study
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Compound 17–Rhabdin
Compound 17 (m/z  671.4) was named rhabdin and its
production was exclusive to the non-aerated broth (NAO) and
SM (Table 2). This compound was purified to >80% (Figures
9A,B). Of the three early eluting peptide-like compounds,
rhabdin is the second most active and inhibited the growth of
FIGURE 7 | Structural analyses of compound 8 – khoicin. (A) UPLC-MS analysis of the purified compound and (B) the extractedm/z chromatogram of the khoicin
ion with m/z 427.302, (C) high resolution MS-MS spectrum of 427.302; (D) proposed working structure for khoicin.
FIGURE 8 | Structural analyses of compound 15 – xenopep. (A) UPLC-MS analysis of the purified compound and (B) the extracted m/z chromatogram of the
xenopep ion withm/z 1,124.364; (C) high resolution MS-MS spectrum of 1,124.364 annotatedwith putative ion identities; (D) proposedworking structure for xenopep;
(E) putative NRPS operon for xenopep with the predicted amino acids for each module (Mod) in the synthetase (SYNT) and probability score (the greater the number the
lower the probability). The amino acids found with amino acid analysis and MS-MS are given in brackets.
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S. aureus, L. monocytogenes, K. pneumoniae, P. aeruginosa and
E. coli (Table 4).
Amino acid analysis conducted on rhabdin indicated the
following amino acid composition: 2xPro, Val, Leu and Phe.
his composition shares some similarities with xenopep. In the
MS-MS structural analysis there was also significant correlation
between the fragments observed for rhabdin and xenopep, with
eight major fragments (m/z  672.4, 383.2, 342.2, 245.1, 229.2,
217.1, 120.1, and 70.1) being identical (Figures 8C, 9C). These
fragments all map to the N-terminal part of xenopep. If the first
three synthetases of the putative xenopep operon is used for
rhabdin synthesis it would suggest the sequence as Val-Haa-Pro-
Pro-Leu-Phe. We confirmed the sequence with MS-MS analysis,
in which the fragmentation yielded classical y’’-ions suggesting a
linear peptide acid (Figures 8C,D).
DISCUSSION
Bacteria from the genus Xenorhabdus are well known for their
ability to produce a wide range of antimicrobial compounds,
active against Gram-positive and -negative bacteria. Here we
report on the activity of X. khoisanae J194 extracts against P.
aeruginosa, E. coli, S. aureus, S. epidermidis and L. monocytogenes
under different culture conditions. A previous study on X.
khoisanae SB10 (Dreyer et al., 2019) also reported activity
against Bacillus subtilis subsp. subtilis and Candida albicans.
This suggests that some strains of X. khoisanae produce a
range of antimicrobial compounds active against bacteria,
yeast and possible also mycelial fungi.
The in situ analysis of the whole genome of X. khoisanae J194
confirmed the identification of xenocoumacin II, PAX peptides and
xenoamicins. The analysis also gave insight into the sequence of two
potential novel peptides, rhabdin and xenopep, identified in this study.
Thewhole genome analysis gave additional support to theMS analysis
that xenopep and rhabdin are novel but related peptides.
PAX 1′, 3′, 5 and 7E and xenocoumacin II were previously
identified in cell-free extracts of X. khoisanae SB 10 (Dreyer et al.,
2019). PAX 7E and PAX1′, 3′ and 5 are lipopeptides known for its
activity against Bacillus subtilis BD170 and E. coli Xen 14
(Gualtieri et al., 2009; Dreyer et al., 2019) and could thus be
present in fractions NAA and NAO. The second known
compound, xenocoumacin II, is known for its antimicrobial
and anti-ulcer activity. Xenocoumacin II is active against S.
aureus and E. coli, as observed in studies on X. nematophilia
(McInerney et al., 1991b) and X. khoisanae SB10 (Dreyer et al.,
2019). It is thus safe to assume that xenocoumacin II, produced by
X. khoisanae J194 and present in the NAA fraction, was below
MIC levels required to kill S. aureus ATCC 25923. The presence
of xenocoumacin II in the NAO and SM fractions could be
responsible for the activity observed against E. coli Xen 14 and S.
aureus ATCC 25923. The production of xenocoumacin in surface
cultures and non-aerated broth indicated a role of oxygen in the
control of its synthesis in this X. khoisanae strain and correlated
FIGURE 9 | Structural analyses of compound 17 – rhabdin. (A) UPLC-MS analysis of the purified compound and (B) the extracted m/z chromatogram of the
rhabdin ion withm/z 671.413; (C) high resolution MS-MS spectrum of 671.413 annotated with putative ion identities; (D) proposed working structure for rhabdin; (E)
putative NRPS operon for xenopep with the predicted amino acids for each module (Mod) in the synthetase (SYNT) and probability score (the greater the number the
lower the probability). The amino acids found with amino acid analysis and MS-MS are given in brackets.
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with the results obtained by Dreyer et al. (2019). Due to its
hydrophobic nature, the third family of compounds,
xenoamicins, eluted much later (Zhou et al., 2013). We show
that the xenoamicins in the produced complex exhibited some
distinctly different fragments when compared to xenoamicin B/C
and G described by Zhou et al. (2013), indicating that the
xenoamicins produced by this strain might be novel. This is
an important finding as xenoamicins are depsipeptides known for
their anti-plasmodial activity (Zhou et al., 2013). However, they
may not have contributed to the antimicrobial activity observed
in NAO and SM fractions. Activity observed against P. aeruginosa
ATCC 27853, S. epidermidis SE1 and L. monocytogenes EDGe is
possibly due to novel compounds such as rhabdin and khoicin.
Khoicin and rhabdin are small early eluting compounds and
provisionally characterized as a tri- and hexapeptide respectively,
that are present in NAO and SM fractions. These could be
responsible for inhibiting P. aeruginosa ATCC 27853, S.
epidermidis SE1 and L. monocytogenes EDGe (Table 2 and
Table 4). The size of both khoicin and rhabdin makes them
ideal candidates for future antibiotics. The lack of known
compounds identified in the AB fraction also indicated that X.
khoisanae produces a plethora of possibly novel compounds, such
as xenopep. Xenopep, a larger peptide also elutes early, but is
primarily produced under aerated conditions, with a putative
NRPS operon in node 7. The fact that a non-classical MS/MS
fragmentation with internal fragments was observed could indicate
that the peptide is modified and/or cyclic. Xenopep and rhabdin,
share structural moieties, such as the sequence Pro-Pro-Leu-Phe.
They may share an operon with differential expression with the
synthetase 4 and 5, only expressed under anaerobic conditions to
yield xenopep, while synthetases 1–3 are expressed under all
conditions to yield rhabdin. The limited amounts of pure
khoicin, rhabdin and xenopep precluded further structural
analyses, which will be addressed in a future study.
Apart from the known compounds and the three novel
compounds in this study an additional 28 compounds were
detected with high ion signals. The bioactivity of these
compounds is unknown and it is possible that strain J194
TABLE 4 | Comparison of the antimicrobial activity spectrum of purified and partially purified novel compounds identified in the four X. khoisanae J194 extracts.
Compound number, proposed
name
Activity against Gram-positive strainsa Activity against Gram-negative strainsa









17, Rhabdin S. aureus ATCC 25923 +++









aActivity +++  very high, ++  high, + medium, if target cell of library tests (refer to methods) is not indicated, no activity was detected. The photos show the clear zones detected with the
well diffusion assay with each of the respective target organisms.
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probably produce compounds with a wider bioactive profile than
recorded in this study.
In an era where there is a dire need for new antibiotics, this
study highlights the potential of discovering novel antibiotics from
the rich complex of antimicrobials produced by X. khoisanae J194.
The use of powerful techniques such as UPLC-MS and HPLC,
combined with advanced microbiological techniques, proved to be
a successful strategy. Further research is required to determine the
full antimicrobial potential of rhabdin and khoicin. This study also
showed the immense influence aeration have on the secondary
metabolism of X. khoisanae J194. Indicating that researchers
should investigate a more diverse range of conditions when
mining for novel antibiotics from microorganisms. The
variation in antimicrobial compounds produced by X.
khoisanae J194 may lead to the discovery of novel antibiotics.
MATERIALS AND METHODS
Isolation, Stock and Growth Conditions of
Strains
Xenorhabdus khoisanae J194 was isolated from the nematode
Steinernema jeffreyense J194 (Dreyer et al., 2017), collected from
soil in the Eastern Cape, South Africa (Malan et al., 2016). Cells of
X. khoisanae J194 were plated onto nutrient agar, supplemented
with 0.025% (w/v) bromothymol blue and 0.04% (w/v) TTC
(NTBA), and incubated at 30°C for a minimum of 48 h. Blue
colonies, representative of cells in phase I (Dreyer et al., 2017), were
selected and cultured in Tryptone Soy Broth (TSB) at 37°C for 24 h
on an orbital shaker. Pure colonies were stored at −80°C in the
presence of 40% (v/v) sterile glycerol. Staphylococcus aureusATCC
25923, S. aureus Xen 31, S. epidermidis SE1, L. monocytogenes
EDGe, E. coliXen 14 and P. aeruginosaATCC27853 were from the
culture collection of the Department of Microbiology, Stellenbosch
University, and were grown in Brain Heart Infusion (BHI). These
strains were streaked to purity on BHI Agar. Colonies were
resuspended into sterile phosphate buffer (PBS), transferred to
80% (v/v) sterile glycerol (final 40%, v/v) and stored at −80°C.
Isolation of Antimicrobial Compounds
Xenorhabdus khoisanae J194 was cultured in TSB for 24 h at 30°C
and then streaked onto Tryptone Soy Agar (TSA). Colonies were
suspended in 5 mL TSB and used as inoculum in each of the three
following culturing methods.
In method A, 10 mL of TSB in a 100 mL Erlenmeyer flask was
inoculated with 100 μL cell suspension and incubated at 26°C for
24, 48, 72 and 96 h, respectively. At each of these time points,
1.0 ml was sampled to record the pH and optical density (OD595).
The pH was of each sample was adjusted to 4.0 with 10.2 M HCl
and kept at 4°C for 3 h. Cells were harvested (5,000 × g, 20 min,
4°C) and the cell-free supernatants (CFSs) concentrated by freeze-
drying. Freeze-dried samples were re-suspended, separately, in
10 mL 75% (v/v) acetonitrile. The acetonitrile upper fraction and
oily bottom fraction were separated by carefully removing the top
layer with a pipette and freeze-dried. Harvested cells were
resuspended in 10 mL 90% (v/v) acetonitrile to extract
intracellular antimicrobial compounds, vortexed and
centrifuged (5,000 × g, for 20 min, 4°C) to remove cell debris.
Cell-free supernatants were concentrated by freeze-drying.
In method B, 250 mL TSB, in a 250 mL Erlenmeyer flask was
inoculated with 2.5 mL active growing cell suspension and
incubated at 26°C for 24, 48, 72 and 96 h, respectively, on an
orbital shaker (220 rpm). Samples (1.0 mL) were collected after 24,
48, 72 and 96 h, and the pH and OD readings determined as
described in method A. At each time point, cells were harvested, as
described above, 10 g Amberlite XAD-16 resin (Sigma-Aldrich,
Missouri, United States) were added to 250 mL cell-free
supernatant (CFS) and left on an orbital shaker (180 rpm) at
4°C for 3 h. The beads were removed by filtration, washed with
1 L of double distilled water and incubated with 30% (v/v) ethanol
(25 mL/5 g) for 30 min to remove weakly bound polar compounds.
After 30min the beads were collected by filtration and ethanol was
washed of with 1 L of double distilled water. The more
hydrophobic and amphipathic compounds were released from
the beads by incubating the beads with 80% (v/v) isopropanol
containing 0.1% (v/v) TFA (trifluoroacetic acid) (ISO-TFA; 40 mL
per 5.0 g) for 1 h. The 80% isopropanol and beads were separated
by filtration and the isopropanol was removed under vacuum,
using a Rotavapor R-114 (Büchi) connected to a water bath (B-480,
Büchi). Further concentration was accomplished by freeze-drying.
In method C, 5.0 mL cell suspension was mixed with 5.0 g
sterile Amberlite XAD-16 resin and then plated onto TSA (TSB
with 2.0%, w/v, agar) in four sets of 150 mm diameter plates. TSB
was pre-treated with Amberlite XAD-16 resin to remove most of
the hydrophobic compounds before agar was added. Plates were
incubated at 26°C for 24, 48, 72 and 96 h, respectively. At each of
these time points, the Amberlite XAD-16 resin were removed
from the surface of the agar with a sterile metal scraper, added to
200 mL analytical quality water and agitated on an orbital shaker
(180 rpm) at 4°C for 1 h. The beads were then collected and
incubated with 30% (v/v) ethanol (25 mL per 5.0 g) as described
above to remove polar compounds. After 30 min the hydrophobic
and amphipathic compounds were released from the Amberlite
XAD-16 resin by incubating the resin in 80% (v/v) isopropanol,
containing 0.1% (v/v) TFA (ISO-TFA; 40 mL per 5.0 g) for 1 h.
The isopropanol and resin were separated as described above and
the isopropanol was removed by evaporation and the
hydrophobic and amphipathic fraction concentrated by freeze-
drying, as described elsewhere.
Antimicrobial Activity Tests
Overnight-grown cultures of S. aureus ATCC 25923, L.
monocytogenes EDGe, E. coli Xen 14 and P. aeruginosa ATCC
27853 were inoculated (1.0%, v/v) into separate volumes of sterile
molten TSA (approximately 45°C), carefully swirled, immediately
transferred to wells (100 µL per well) in a 96-well microtiter plate
(Greiner Bio-One, Austria) and left to solidify. Refer to Du Toit
and Rautenbach (2000) for a more detailed description. Freeze-
dried fractions were each suspended in 50% (v/v) acetonitrile in
water to yield a final volume of 1.0 mL. Twentymicroliters of each
suspension of the freeze-dried crude extracts (24, 48, 72, and 96 h)
were added onto the surface of TSA-imbedded cells in the 96-well
plate and the plate was incubated for 24 h at 37°C. Optical density
readings (595 nm) were recorded for each well before and after
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24 h of incubation at 37°C, using an iMark Microplate reader
(Biorad, California, United States).
Activity assays of the 96 h crude extracts were repeated to
determine specific activity. Freeze-dried CFS collected from 96 h-
old cultures were each re-suspended in sterile distilled water
(4.0 mg/mL) and antimicrobial activity tested against P.
aeruginosa ATCC 27853, E. coli Xen 14, S. aureus
ATCC 25923, S. aureus Xen 31, S. epidermidis SE1 and L.
monocytogenes EDGe. The strains were inoculated (1.0%, v/v)
into separate volumes of sterile molten TSA (approximately
45°C), carefully mixed and immediately transferred to round
petri dishes of 145 mm in diameter in the first step of the well
diffusion agar assay. A 96-well PCR plate was sterilized under
UV, placed into the inoculated molten agar and the agar was
allowed to set before the PCR plate were removed. Once the agar
was set, 20.0 µL crude extract was placed into each well and
incubated for 24 h at 37°C. The same method was used to
determine the antimicrobial activity of the partially purified
compounds, except all the fractions collected were dissolved in
100 µL of 50% acetonitrile. Specific activity was determined using
the following equation:
Specific activity  area/mL
4.00 mg/mL
In Situ Identification of Putative Operons
The whole genome of X. khoisanae J194 was subjected to
AntiSMASH (Antismash.secondarymetabolites.org) to identify
secondary metabolites biosynthesis gene clusters (Blin et al.,
2019). The whole genome was also analyzed for putative
operons relating to rhabdin and xenopep. Operons were
identified by aligning the protein sequence of gramicidin S
and tyrocidine synthetases to the whole genome sequence of
X. khoisanae J194 using the tblastn function of the NCBI website
(blast.ncbi.nlm.nih.gov/Blast.cgi). The open reading frames of the
possible operons were translated to protein sequence using the
CLC Main Workbench 7.6.1 software. Thereafter the various
domains present in non-ribosomal peptide (NRP) synthetases
(condensation, adenylation, epimerization, thiolation and
thioesterase) were identified by searching for the highly
conserved core motifs of the catalytic NRP domains. The
synthetases identified were subjected to the LSI based
A-domain function predictor (http://bioserv7.bioinfo.pbf.hr/
LSIpredictor/AdomainPrediction.jsp), the NRPSsp adenylation
domain predictor (http://www.nrpssp.com) and the PKS/NRPS
Web Server/Predictive Blast Server (http://sourceforge.net/
projects/secmetdb/). Validity of the prediction was based on
the prediction score given by the software.
Partial Purification of Antimicrobial
Compounds
Compounds produced by X. khoisanae J194 cultured on solid
media were extracted and partially purified by means of high-
performance liquid chromatography (HPLC; Agilent,
California, United States). The freeze-dried extract was
dissolved in 50% (v/v) acetonitrile and loaded onto a
Poroshell 120 EC-C18 HPLC column (120 Å, 4 μm, 4.6 mm
× 150 mm, Agilent) and eluted with a linear gradient created
with 0.1% (v/v) trifluoracetic acid (TFA) in analytically pure
water (eluent A) and 0.1% (v/v) TFA in acetonitrile (eluent B).
The flow rate was set at 1.5 mL/min and the elution program
utilized was as follows: 20% eluent A from 0 to 0.5 min (initial
conditions), 0.5–12.5 min linear gradient from 20 to 90%
eluent B, 12.5–13 min linear gradient from 90 to 100%
eluent B, 13–14 min at 100% eluent B, followed by column
equilibration (14–20 min linear gradient from 100 to 20%
eluent B and 20–25 min at initial conditions). Separation
was performed on an Agilent 1260 Infinity II LC system.
Data were recorded at 230 and 245 nm. Fractions of the
peaks were collected, freeze-dried and tested for
antimicrobial activity as described above.
Identification of Antimicrobial Compounds
Samples that were active against one or more of the target strains
were analyzed using a Waters Acquity UPLC™ (ultraperformance
liquid chromatography), linked to aWaters Synapt G2 quadrupole
time-of-flight mass spectrometer (QTOF; Waters Corporation,
Milford, United States) housed at the Central Analytical Facility
at Stellenbosch University. Sample volumes of 1.0–5.0 µL were
analyzed on a HSS T3 column (1.8 µm, 2.1 mm × 100 mm)
developed with an elution program created with 0.1% (v/v)
formic acid in analytically pure water (eluent A) and 0.1% (v/v)
formic acid in acetonitrile (eluent B). The flow rate was set at
300 µL/min and the elution program utilized was as follows: 100%
eluent A from 0 to 0.5 min (initial conditions), 0.5–1.0 min linear
gradient from 0 to 30.0% eluent B, 1.0–10.0 min linear gradient
from 30.0 to 60.0% eluent B, 10–15min linear gradient from 60.0
to 80.0% eluent B, followed by column equilibration
(15.0–15.1 min linear gradient from 80.0 B to 100% A and
15.1–20.0 min at initial conditions). The rest of the instrument
settings for mass spectrometric analysis were as follows: cone
voltage 15 V, capillary voltage 2.5 kV, extraction cone voltage
4 V, source temperature 120°C, desolvation gas (N2) of 650 L/h
and temperature 275°C. Spectral data were collected in positive
mode by scanning throughm/z  100 to 2000 in continuummode.
Mass-spectrometry data of the detected ion peaks in
chromatography of the different samples were processed with
the MaxEnt 3 function of MassLynx 4.1. For comparison of
samples, signals were normalized to the highest signal over a
specific elution range (0–6 min and 6–17min).
Preliminary structure analysis was done by high resolution
collision induced dissociation (CID) analyses in the MSE mode
(tandemMS or MS/MS) during UHPLC-MS and monitored on a
second MS channel, as described by Dreyer et al. (2019). A
collision energy gradient of 20–60 eV at 1 s MS/MS scan time
were used for CID and data was collected in the second mass
analyser (MS2) through m/z  40 to 2000 in continuum mode.
Reliable high-resolution MS data was ensured by calibrating
the MS instrument with sodium formate. A single point lock
spray (leucine encephalin,m/z  556.2771) was used as a calibrant
during analysis to compensate for any m/z drift. Elemental
composition was fitted using Masslynx software and formulas
were considered that has a mass accuracy of 5 ppm or better. The
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elution time, number of hetero atoms, isotope patterns and
double bond equivalence were taken into consideration when
probable formulas (elementary composition) were selected.
Candidate formulas were not selected for larger molecules, due
to high number of possibilities, and therefore a high uncertainty,
unless they were previously identified compounds.
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